Lipid and lipoprotein parameters at baseline and drug treatment meteor trial l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 4

Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial PowerPoint PPT Presentation


  • 116 Views
  • Uploaded on
  • Presentation posted in: General

Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial.

Download Presentation

Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Lipid and lipoprotein parameters at baseline and drug treatment meteor trial l.jpg

Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial

Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein.SI conversion factors: To convert HDL, LDL, and total cholesterol to mmol/L, multiply by 0.0259; triglycerides to mmol/L, multiply by 0.0113.*Time-weighted average was defined as the lipid value multiplied by number of days since the last lipid assessment, summed for all lipid observations and divided by the sum of days between all visits. Results are least-squares means from analysis of covariance.

Crouse JR et al. JAMA 2007;297:1344-1353


Lipid and lipoprotein parameters at baseline and drug treatment meteor trial2 l.jpg

Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial

Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein.SI conversion factors: To convert HDL, LDL, and total cholesterol to mmol/L, multiply by 0.0259; triglycerides to mmol/L, multiply by 0.0113.†P<.001 for all comparisons of rosuvastatin with placebo.

Crouse JR et al. JAMA 2007;297:1344-1353


Changes in the primary and secondary end points meteor trial l.jpg

Changes in the Primary and Secondary End Points: METEOR Trial

Abbreviations: CI, confidence interval; CIMT, carotid intima-media thickness

Crouse JR et al. JAMA 2007;297:1344-1353


Change in maximum carotid intima media thickness cimt for the primary end point meteor trial l.jpg

Placebo

Rosuvastatin

Change in Maximum CIMT, mm

0

6

12

18

24

Time, mo

Change in Maximum Carotid Intima-Media Thickness (CIMT) for the Primary End Point: METEOR Trial

Crouse JR et al. JAMA 2007;297:1344-1353


  • Login